Metoject

Methotrexate, the active ingredient in Metoject, is an antimetabolite (folate antagonist) presented as a subcutaneous formulation for injection use. It is employed to treat autoimmune disorders and certain cancers in adult patients. GNH USA supplies Metoject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoject (Methotrexate) acts on rapidly dividing cells and modulates immune activity, making it useful for several disease groups. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: limits skin cell proliferation and improves plaque severity. - Acute lymphoblastic leukemia: interferes with malignant cell DNA synthesis to achieve remission. - Lymphoma: inhibits growth of malignant lymphoid cells, supporting disease control.

Metoject may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting: gastrointestinal upset that may be transient. - Fatigue: feeling of tiredness or reduced energy. - Mouth sores: ulceration of oral mucosa. - Elevated liver enzymes: mild hepatic enzyme rise on laboratory testing. - Low blood cell counts: mild reductions in white cells or platelets.

Serious or Rare Side Effects: - Severe liver toxicity: potential for hepatitis or fibrosis. - Pulmonary fibrosis: progressive lung scarring affecting breathing. - Bone marrow suppression: profound pancytopenia requiring medical intervention. - Renal impairment: decreased kidney function leading to drug accumulation. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before using Metoject, consider the following safety measures. - Pregnancy: contraindicated in pregnancy (Category X) due to teratogenic risk. - Liver function: monitor hepatic enzymes regularly; avoid use in severe liver disease. - Renal function: assess creatinine clearance; dose adjustment may be needed. - Blood counts: perform complete blood count monitoring to detect cytopenias. - Infections: screen for latent infections and avoid use in active severe infections. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Proton pump inhibitors (e.g., omeprazole): may raise serum methotrexate levels. - Trimethoprim‑sulfamethoxazole: enhances risk of bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Azathioprine or mycophenolate: additive immunosuppression requiring blood count monitoring. - Live vaccines: reduced efficacy and potential infection risk. - Penicillins (high‑dose): may decrease methotrexate clearance.